Selank 129954-34-3 /dihexa / Semax/N acetyl selank /epitalon/ 10mg/Vials 1g

Selank peptide

Selank peptide;SelankAcetate;PL14736;L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-proline;L-THREONYL-L-LYSYL-L-PROLYL-L-ARGINYL-L-PROLYLGLYCYL-L-PROLINE; MONOACETATE;H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH;SLANK;Selank peptid

129954-34-3

C33H57N11O9

JTDTXGMXNXBGBZ-YVHUGQOKSA-N

751.87

751.43407244

232-660-2

TS9JR8EP1G

Bulk Drug Intermediates

1.53±0.1 g/cm3(Predicted)

134-136 °C

3.43±0.20(Predicted)

Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator

Research compound — Not FDA approved

A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.

65 pM

Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).

Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.

NCT04488419

PubChem

9WYX65A5C2

Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status

Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.